EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Extended repertoire of CXC chemokines acting as agonists and antagonists of the human and murine atypical chemokine receptor ACKR2

Rafael Luís, Brian F Volkman iD, Martyna Szpakowska iD, Andy Chevigné iD

Journal of Leukocyte Biology · 23.04.2025 · 117 (4)

DOI: 10.1093/jleuko/qiaf013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 04.02.2025. Verfasst von Rafael Luís und 3 weiteren Autor:innen. Beteiligte Einrichtung: Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), 29, rue Henri Koch, L-4354 Esch-su…. Hauptthemen laut MEDLINE: Receptors, Chemokine, Chemokines, CXC. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, US National Institutes of Health, Luxembourg National Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atypical chemokine receptors are a subfamily of important regulators of chemokine functions. Among them, ACKR2 has long been considered a scavenger of multiple inflammatory chemokines exclusively from the CC family. Recently, we demonstrated the ability of ACKR2 to scavenge the CXC chemokine CXCL10, previously reported to bind solely the classical receptor CXCR3. This discovery emphasized the need for systematic reassessments of chemokine–receptor pairings. In this work, we established a highly sensitive NanoBRET-based competition binding assay using a novel proprietary ACKR2 modulator (LIH222) and applied it in a comprehensive reassessment of the pairings between human and murine chemokines and their respective ACKR2 orthologs. We confirmed CXCL10 as a ligand for the human but also the mouse ACKR2. We also identified CXCL5, CXCL11, and CXCL12 as new CXC chemokines for both ACKR2 orthologs. Furthermore, we showed that CXCL2 is a ligand for the human but not the mouse ACKR2, whereas CXCL1 binds the mouse but not the human receptor. Finally, we found that N-terminally truncated CXCL5 (CXCL58-78) loses its capacity to bind ACKR2, whereas the removal of the first 2 residues of CXCL11 (CXCL113-73) enhances its antagonist potency, showing a tendency toward a reduction of the receptor basal interactions with β-arrestins. Altogether, this study demonstrates that ACKR2 is not exclusive to CC chemokines, and although with a weaker affinity, it can also bind and scavenge a subset of inflammatory and homeostatic CXC chemokines important for the regulation of the immune system.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ChemokineChemokines, CXCAnimalsHumansMiceChemokine CXCL11Chemokine CXCL10LigandsProtein BindingChemokine CXCL5Chemokine CXCL12Chemokine Receptor D6

Stichwörter der Autor:innen

ACKR3CXCL1CXCL10CXCL11CXCL12CXCL2CXCL5CXCR3d6

Substanzen

Receptors, ChemokineACKR2 protein, humanChemokines, CXCAckr2 protein, mouseChemokine CXCL11Chemokine CXCL10LigandsChemokine CXCL5Chemokine CXCL12Chemokine Receptor D6

Autor:innen und Institutionen

  • Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH), 29, rue Henri Koch, L-4354 Esch-sur-Alzette, Luxembourg.
  • Faculty of Science, Technology and Medicine, University of Luxembourg, 2, place de l'Université, L-4365 Esch-sur-Alzette, Luxembourg.
  • Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, United States.

ORCID-Profile: Brian F Volkman, Martyna Szpakowska, Andy Chevigné

Förderung

  • NIAID NIH HHS
  • US National Institutes of Health
  • Luxembourg National Research Fund
  • Luxembourg Institute of Health
  • Cancer Foundation Luxembourg and the Luxembourg National Research Fund
  • Marie Skłodowska-Curie Innovative Training Network ONCORNET2.0 "ONCOgenic Receptor Network of Excellence and Training"
  • Marie Skłodowska-Curie Innovative Training Network ONCORNET2.0 “ONCOgenic Receptor Network of Excellence and Training”

Zitieren

APA

Luís, R., Volkman, B. F., Szpakowska, M., & Chevigné, A. (2025). Extended repertoire of CXC chemokines acting as agonists and antagonists of the human and murine atypical chemokine receptor ACKR2. Journal of Leukocyte Biology, 117(4). https://doi.org/10.1093/jleuko/qiaf013

Vancouver

Luís R, Volkman BF, Szpakowska M, Chevigné A. Extended repertoire of CXC chemokines acting as agonists and antagonists of the human and murine atypical chemokine receptor ACKR2. Journal of Leukocyte Biology. 2025;117(4). doi:10.1093/jleuko/qiaf013

BibTeX
@article{Lus2025,
  author = {Luís, Rafael and Volkman, Brian F and Szpakowska, Martyna and Chevigné, Andy},
  title = {Extended repertoire of CXC chemokines acting as agonists and antagonists of the human and murine atypical chemokine receptor ACKR2},
  journal = {Journal of Leukocyte Biology},
  year = {2025},
  volume = {117},
  number = {4},
  doi = {10.1093/jleuko/qiaf013}
}
Kostenlos starten →